NCT04868708View on ClinicalTrials.gov

A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

February 28, 2024

Study Completion Date

February 28, 2024

Conditions
Recurrent or Metastatic Cervical Cancer
Interventions
BIOLOGICAL

AK104

Subjects will receive AK104 intravenously.

BIOLOGICAL

Bevacizumab

Subjects will receive Bevacizumab intravenously.

DRUG

Paclitaxel

Subjects will receive Paclitaxel intravenously.

DRUG

Cisplatin or Carboplatin

Subjects will receive Cisplatin or Carboplatin intravenously.

Trial Locations (2)

310022

Zhejiang Cancer Hospital, Hangzhou

410013

Hunan Cancer Hospital, Changsha

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY

NCT04868708 - A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer | Biotech Hunter | Biotech Hunter